cannabis indica

Canabinoides Sintéticos HU-x

termo de indexação original: HU-x Synthetic Cannabinoids

O que é Canabinoides Sintéticos HU-x

A série HU — de Hebrew University — vem do laboratório de Raphael Mechoulam, o mesmo grupo que isolou o THC e identificou a anandamida.

Inclui compostos de referência em pesquisa: o HU-210, agonista canabinoide extremamente potente, muito acima do THC; o HU-308, agonista seletivo do CB2, útil para investigar efeitos periféricos sem envolver o sistema nervoso central; e o HU-331, derivado do CBD com estrutura de quinona, estudado em oncologia experimental.

A seletividade é o que dá valor a esses compostos. Um agonista que atinge só o CB2 permite separar o que é efeito imunológico do que é efeito neurológico — algo que o THC, que ativa os dois, não permite.

No acervo

O acervo do Cannabis Indica reúne 155 estudos científicos que tocam o composto Canabinoides Sintéticos HU-x, publicados entre 1989 e 2023. Pela leitura automatizada, 126 (81%) foram classificados como favoráveis, 19 (12%) como inconclusivos e 10 (6%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é estudo em animais (72 estudos), seguido de metanálise (60). As condições mais associadas são Dor, Inflamação e Câncer.

Estudos indexados
155
Período coberto
1989–2023
Favoráveis
126 · 81%
Inconclusivos
19 · 12%
Desfavoráveis
10 · 6%
Termo original
HU-x Synthetic Cannabinoids

O acervo em números

Tipo de estudo

Estudo em Animais72
Metanálise60
Estudo Laboratorial20
Ensaio Clínico2
Ensaio Clínico Duplo-Cego1

Direção do resultado

Favorável126
Inconclusivo19
Desfavorável10

Por década

1980s3
1990s11
2000s38
2010s59
2020s44

155 estudos

Filtrar e buscar no acervo →
  1. 2023

    CB1 receptor expression and signaling are required for dexamethasone-induced aversive memory consolidation

  2. 2023

    Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  3. 2023

    Hippocampal CB1 receptor mediates antidepressant-like effect of synthetic cannabinoid-HU210 in acute despair reaction model in mice

    FavorávelEstudo em AnimaisDepressãoEstresse Oxidativo
  4. 2023

    The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology

  5. 2022

    Association of cannabinoid receptor modulation with normal and abnormal skeletal remodelling: A systematic review and meta-analysis of in vitro, in vivo and human studies

  6. 2022

    Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice

  7. 2022

    Cannabinoids as anticancer drugs: current status of preclinical research

  8. 2022

    Cannabinoids in rheumatology: Friend, foe or a bystander?

  9. 2022

    Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming

  10. 2022

    Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

    FavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+28
  11. 2022

    Deficiency of autism-related Scn2a gene in mice disrupts sleep patterns and circadian rhythms

    FavorávelEstudo em AnimaisAutismo
  12. 2022

    Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  13. 2022

    Endocannabinoid signaling in glioma

  14. 2022

    Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story?

  15. 2022

    G Protein-Coupled Receptors in Osteoarthritis

  16. 2022

    HU308 Mitigates Osteoarthritis by Stimulating Sox9-Related Networks of Carbohydrate Metabolism

    FavorávelEstudo em AnimaisDorArtriteArtrite — Osteoartrite
  17. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  18. 2022

    In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+14
  19. 2022

    Interaction of Glia Cells with Glioblastoma and Melanoma Cells under the Influence of Phytocannabinoids

    DesfavorávelEstudo LaboratorialCâncerCâncer — CérebroCâncer — Melanoma+1
  20. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  21. 2022

    Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  22. 2022

    Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies

  23. 2022

    Synaptic changes induced by cannabinoid drugs and cannabis use disorder

  24. 2022

    The Metabolic Efficacy of a Cannabidiolic Acid (CBDA) Derivative in Treating Diet- and Genetic-Induced Obesity

    FavorávelEstudo em AnimaisObesidadeSíndrome MetabólicaÁcido Canabidiólico (CBD-a)
  25. 2022

    The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer

    InconclusivoMetanáliseDorCâncerObesidadeAnandamida (AEA)Tetraidrocanabinol (THC)+17
  26. 2022

    Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation

  27. 2022

    Unexpected short- and long-term effects of chronic adolescent HU-210 exposure on emotional behavior

    InconclusivoEstudo em AnimaisAnsiedadeDepressãoIntoxicação por Cannabis Sintética
  28. 2022

    Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

  29. 2021

    Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes

  30. 2021

    Cannabidiol oxidation product HU-331 is a potential anticancer cannabinoid-quinone: a narrative review

    FavorávelMetanáliseCâncer
  31. 2021

    Cannabinoid Quinones—A Review and Novel Observations

    FavorávelMetanáliseCâncerInflamaçãoEstresse OxidativoCanabinol (CBN)+7
  32. 2021

    Cannabinoids Drugs and Oral Health-From Recreational Side-Effects to Medicinal Purposes: A Systematic Review

  33. 2021

    Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+17
  34. 2021

    Effect of Cannabinoid 2 Receptor Modulation on the Peripheral Immune Response in Central Nervous System Injury-Induced Immunodeficiency Syndrome

  35. 2021

    Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review

  36. 2021

    Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence

  37. 2021

    Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates

  38. 2021

    Synthetic Cannabinoids and Cathinones Cardiotoxicity: Facts and Perspectives

  39. 2021

    Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review

  40. 2021

    The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis

  41. 2021

    The Current and Potential Application of Medicinal Cannabis Products in Dentistry

  42. 2020

    Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews

  43. 2020

    Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats

  44. 2020

    Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia

    FavorávelEstudo em AnimaisDoença de Parkinson
  45. 2019

    Antiallodynic Effects of Cannabinoid Receptor 2 (CB2R) Agonists on Retrovirus Infection-Induced Neuropathic Pain

  46. 2019

    Cannabinoid 2 Receptor-Based Modulation of the Immune Response in Experimental Models of CNS Injury

    FavorávelMetanáliseImunodeficiência por TraumaCanabinoides Sintéticos AM-x
  47. 2019

    Cannabinoids and bone regeneration

    FavorávelMetanáliseFraturas ÓsseasAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  48. 2019

    Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

  49. 2019

    Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease

  50. 2019

    HU-671, a Novel Oleoyl Serine Derivative, Exhibits Enhanced Efficacy in Reversing Ovariectomy-Induced Osteoporosis and Bone Marrow Adiposity

    FavorávelEstudo em AnimaisOsteoporose
  51. 2019

    Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye

    FavorávelEstudo em AnimaisUveíte
  52. 2019

    Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury

    FavorávelEstudo em AnimaisTraumatismo Cranioencefálico
  53. 2019

    Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?

  54. 2018

    Acute oral Cannabidiolic Acid Methyl Ester reduces depression-like behavior in two genetic animal models of depression.

    FavorávelEstudo em AnimaisAnsiedadeDepressãoÁcido Canabidiólico (CBD-a)
  55. 2018

    Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease

    FavorávelMetanáliseAnandamida (AEA)Hidrolase de Amidas de Ácidos Graxos (FAAH)+4
  56. 2018

    Cannabinoid-mediated retinal rescue correlates with improved circadian parameters in retinal dystrophic rats.

    FavorávelEstudo em AnimaisInsônia e Distúrbios do SonoDoenças da Retina
  57. 2018

    Cannabinoids, the Heart of the Matter.

  58. 2018

    Chronic Stress Induces Anxiety via an Amygdalar Intracellular Cascade that Impairs Endocannabinoid Signaling.

    FavorávelEstudo em AnimaisAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  59. 2018

    Endocannabinoids in Body Weight Control

    FavorávelMetanáliseObesidadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+6
  60. 2018

    Neuroprotection by (Endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases

  61. 2018

    Perioperative Management of Severe Traumatic Brain Injury: What Is New?

    FavorávelMetanáliseInflamaçãoTraumatismo Cranioencefálico
  62. 2018

    The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation.

  63. 2018

    The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

  64. 2017

    Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats

  65. 2017

    Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

    FavorávelEstudo em AnimaisInflamaçãoDoenças da RetinaCanabinoides Sintéticos AM-x
  66. 2017

    Cannabinoids and the kidney: effects in health and disease

  67. 2017

    Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

  68. 2017

    Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.

  69. 2017

    Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles

    FavorávelEstudo em AnimaisDepressãoCúrcuma
  70. 2017

    The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis

  71. 2017

    The Clinical Significance of Endocannabinoids in Endometriosis Pain Management

    FavorávelMetanáliseEndometrioseAnandamida (AEA)Tetraidrocanabinol (THC)+5
  72. 2016

    Anti-Inflammatory and Osteoprotective Effects of Cannabinoid-2 Receptor Agonist HU-308 in a Rat Model of Lipopolysaccharide-Induced Periodontitis

    FavorávelEstudo em AnimaisDoença PeriodontalDor — Dentária Aguda
  73. 2016

    Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression

    FavorávelEstudo em AnimaisDepressãoCúrcuma
  74. 2016

    Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting.

  75. 2016

    Endocannabinoids in the Gut

  76. 2016

    Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

  77. 2016

    Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects

    FavorávelEstudo em AnimaisAnsiedadeDepressãoPsicoseCanabinoides Sintéticos AM-x+2
  78. 2016

    Modulation of cellular redox homeostasis by the endocannabinoid system.

  79. 2016

    Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.

    FavorávelEstudo em AnimaisDoença de Parkinson
  80. 2016

    Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model.

  81. 2015

    Cannabinoids in experimental stroke: a systematic review and meta-analysis

    FavorávelEstudo em AnimaisAVCAnandamida (AEA)Tetraidrocanabinol (THC)+6
  82. 2015

    HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid

    FavorávelEstudo em AnimaisInflamaçãoArtriteArtrite — Reumatoide+1
  83. 2015

    Intraperirhinal cortex administration of the synthetic cannabinoid, HU210, disrupts object recognition memory in rats

  84. 2015

    New horizons for newborn brain protection: enhancing endogenous neuroprotection

  85. 2015

    Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  86. 2015

    Ultra Low Dose Delta 9-Tetrahydrocannabinol Protects Mouse Liver from Ischemia Reperfusion Injury.

  87. 2014

    Anti-inflammatory effects of cannabinoid CB2 receptor activation in endotoxin-induced uveitis.

    FavorávelEstudo em AnimaisUveíteCanabinoides Sintéticos AM-x
  88. 2014

    Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system

  89. 2014

    Experimental Cannabinoid 2 Receptor-Mediated Immune Modulation in Sepsis.

  90. 2014

    Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis

    FavorávelEstudo LaboratorialArtriteArtrite — Reumatoide
  91. 2014

    Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration

    FavorávelEstudo em AnimaisDoenças da RetinaDegeneração Macular
  92. 2014

    Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs

  93. 2014

    Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage.

  94. 2013

    Prospects for cannabinoid therapies in viral encephalitis.

    FavorávelEstudo em AnimaisEncefalite e MieliteCanabinoides Sintéticos WIN-x
  95. 2012

    Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids

    InconclusivoEstudo LaboratorialDorCâncerCanabinoides Sintéticos AM-xCanabinoides Sintéticos WIN-x+10
  96. 2011

    Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation

    FavorávelEstudo em AnimaisDoença de ParkinsonCanabinoides Sintéticos WIN-x
  97. 2011

    Endocannabinoids in Liver Disease

  98. 2010

    Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.

    FavorávelEstudo em AnimaisDoença de HuntingtonHidrolase de Amidas de Ácidos Graxos (FAAH)
  99. 2010

    Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease

    FavorávelMetanáliseInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+5
  100. 2010

    Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress and cell death in nephropathy.

    FavorávelEstudo em AnimaisEstresse OxidativoNefropatia Induzida por Medicamentos
  101. 2010

    Do Cannabinoids have a therapeutic role in transplantation?

  102. 2010

    Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.

    FavorávelEstudo LaboratorialDoença de Huntington
  103. 2010

    The endocannabinoid system links gut microbiota to adipogenesis

  104. 2009

    Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy.

    FavorávelEstudo LaboratorialDorDiabetesDor — Neuropatia DiabéticaCanabinoides Sintéticos AM-x
  105. 2009

    Cannabinoid Receptor 1 Is A Potential Drug Target For Treatment Of Translocation-positive Rhabdomyosarcoma

    FavorávelEstudo LaboratorialCâncerCâncer — Tecidos Moles
  106. 2008

    Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice

  107. 2008

    Peroxisome Proliferator-Activated Receptors: “Key” Regulators of Neuroinflammation after Traumatic Brain Injury

  108. 2008

    Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells

    InconclusivoEstudo LaboratorialCâncerCâncer — NeuroblastomaCanabinoides Sintéticos CP-x
  109. 2008

    Role of cannabinoids in chronic liver diseases

  110. 2007

    Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

  111. 2007

    Cannabinoids in health and disease

  112. 2007

    Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis

  113. 2007

    Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties

    FavorávelEstudo em AnimaisDoença de Parkinson
  114. 2007

    HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor

    FavorávelEstudo em AnimaisCâncerEstresse OxidativoCâncer — MamaCanabinoides Sintéticos SR-x+2
  115. 2007

    Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect.

  116. 2007

    Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity

  117. 2007

    The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.

    FavorávelEnsaio ClínicoEsclerose MúltiplaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  118. 2006

    Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.

  119. 2006

    Peripheral cannabinoid receptor, CB2, regulates bone mass

    FavorávelEstudo em AnimaisCondições GeriátricasOsteoporoseLongevidade
  120. 2006

    Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite.

    FavorávelEstudo em AnimaisEsclerose MúltiplaTraumatismo Cranioencefálico
  121. 2005

    Cannabinoid CB2 Receptor Agonist Activity in the Hindpaw Incision Model of Postoperative Pain

  122. 2005

    Cannabinoids Promote Embryonic And Adult Hippocampus Neurogenesis And Produce Anxiolytic- And Antidepressant-like Effects

    FavorávelEstudo em AnimaisAnsiedadeDepressãoDisfunção Cognitiva+2
  123. 2005

    Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

    FavorávelEstudo em AnimaisDoença de Parkinson
  124. 2005

    Prevention Of Alzheimer's Disease Pathology By Cannabinoids: Neuroprotection Mediated By Blockade Of Microglial Activation

  125. 2005

    Therapeutic opportunities through modulation of the endocannabinoid system

  126. 2004

    Cannabinoids and glaucoma.

    FavorávelMetanáliseGlaucomaTetraidrocanabinol (THC)
  127. 2004

    Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors

    FavorávelEstudo LaboratorialTetraidrocanabinol (THC)Canabinoides Sintéticos WIN-x+3
  128. 2004

    Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension.

  129. 2003

    CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?

  130. 2003

    Drug-induced Hypothermia Reduces Ischemic Damage: Effects of the Cannabinoid HU-210

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)EpilepsiaEstresse Oxidativo+3
  131. 2003

    Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin

    DesfavorávelEnsaio ClínicoDermatite de Contato Alérgica
  132. 2002

    Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial

    FavorávelEnsaio Clínico Duplo-CegoTraumatismo Cranioencefálico
  133. 2002

    Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease

    FavorávelEstudo LaboratorialCâncerCâncer — LinfomaAnandamida (AEA)Tetraidrocanabinol (THC)+1
  134. 2001

    Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit

    FavorávelEstudo em AnimaisLesões da Medula EspinhalCanabinoides Sintéticos SR-x
  135. 2001

    CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells

    InconclusivoEstudo em AnimaisCâncerCâncer — Neuroblastoma
  136. 2001

    Endogenous Cannabinoid, 2-arachidonoylglycerol, Attenuates Naloxone-precipitated Withdrawal Signs In Morphine-dependent Mice

  137. 2001

    Hu 210: a potent tool for investigations of the cannabinoid system

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+4
  138. 2000

    Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats

    FavorávelEstudo em AnimaisDorInflamaçãoDor — CrônicaCanabinoides Sintéticos SR-x+2
  139. 2000

    Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats

    FavorávelEstudo em AnimaisObesidadeSíndrome Metabólica
  140. 2000

    Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour

    DesfavorávelEstudo em AnimaisIntoxicação por Cannabis SintéticaLibidoDisfunção Erétil
  141. 2000

    Suppression Of Nerve Growth Factor Trk Receptors And Prolactin Receptors By Endocannabinoids Leads To Inhibition Of Human Breast And Prostate Cancer Cell Proliferation

  142. 1999

    Cannabinoids as antioxidants and neuroprotectants.

  143. 1999

    Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task

    DesfavorávelEstudo em AnimaisEfeitos Adversos da CannabisIntoxicação por Cannabis Sintética
  144. 1999

    Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.

  145. 1998

    Cannabidiol and Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

  146. 1998

    Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla

    FavorávelEstudo em AnimaisDorDor — CrônicaDor — Aguda
  147. 1998

    The Endogenous Cannabinoid Anandamide Inhibits Human Breast Cancer Cell Proliferation

    FavorávelEstudo LaboratorialCâncerCâncer — MamaAnandamida (AEA)
  148. 1997

    Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant

    FavorávelEstudo em AnimaisTraumatismo Cranioencefálico
  149. 1997

    Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid

    FavorávelEstudo em AnimaisSepseSíndrome do Choque Tóxico
  150. 1996

    A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis.

    FavorávelEstudo em AnimaisMeningite Bacteriana
  151. 1995

    Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors

    InconclusivoEstudo LaboratorialAnandamida (AEA)Tetraidrocanabinol (THC)+3
  152. 1993

    The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain

    FavorávelEstudo LaboratorialDoenças NeurodegenerativasExcitotoxicidade
  153. 1989

    Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid

  154. 1989

    Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs

    InconclusivoEstudo em AnimaisEfeitos Adversos da Cannabis
  155. 1989

    Stereospecific effects of (-)- and (+)-7-hydroxy-delta-6-tetrahydrocannabinol-dimethylheptyl on the immune system of mice

    InconclusivoEstudo em Animais

Continue por aqui

Perguntas frequentes

Quantos estudos sobre canabinoides sintéticos hu-x estão indexados no acervo?
São 155 estudos, publicados entre 1989 e 2023. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Estudo em Animais: 72 · Metanálise: 60 · Estudo Laboratorial: 20 · Ensaio Clínico: 2 · Ensaio Clínico Duplo-Cego: 1. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 126 favoráveis, 19 inconclusivos e 10 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Canabinoides Sintéticos HU-x — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/canabinoide/canabinoides-sinteticos-hu-x/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Canabinoides Sintéticos HU-x — estudos científicos sobre cannabis. https://cannabisindica.com.br/canabinoide/canabinoides-sinteticos-hu-x/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.